ME02637B - Antitela za receptor 3 faktora rasta epiderma (her3) - Google Patents

Antitela za receptor 3 faktora rasta epiderma (her3)

Info

Publication number
ME02637B
ME02637B MEP-2017-65A MEP6517A ME02637B ME 02637 B ME02637 B ME 02637B ME P6517 A MEP6517 A ME P6517A ME 02637 B ME02637 B ME 02637B
Authority
ME
Montenegro
Prior art keywords
sequence
seq
fragment
her3
antibody
Prior art date
Application number
MEP-2017-65A
Other languages
German (de)
English (en)
French (fr)
Inventor
Winfried Elis
Seth Ettenberg
Andrew Paul Garner
Nicole Haubst
Christian Carsten Silvester Kunz
Sprague Elizabeth Anne Reisinger
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44630597&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ME02637(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of ME02637B publication Critical patent/ME02637B/me

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3015—Breast
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3023—Lung
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/303—Liver or Pancreas
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3038—Kidney, bladder
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3046—Stomach, Intestines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3053—Skin, nerves, brain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3061—Blood cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/522—CH1 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Reproductive Health (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Neurology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Gynecology & Obstetrics (AREA)
  • Dermatology (AREA)
  • Neurosurgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Pulmonology (AREA)
  • Peptides Or Proteins (AREA)

Claims (35)

1.Izolovano antitelo ili njegov fragment koji prepoznaje konformacioni epitop HER3 receptora, naznačeno time što konformacioni epitop uključuje aminokiselinske rezidue 265-277, 315 unutar domena 2 i aminokiselinske rezidue 571, 582-584, 596-597, 600-602, 609-615 unutar domena 4 HER3 receptora, i naznačeno time što antitelo ili njegov fragment blokiraju i ligand-zavisni i ligand-nezavisni prenos signala.
2.Izolovano antitelo ili njegov fragment iz patentnog zahteva 1, naznačeno time što se antitelo ili njegov fragment: a) vezuje za HER3 receptor u neaktivnom stanju; ili b) stabilizuje HER3 receptor u neaktivnom stanju.
3.Izolovano antitelo ili njegov fragment prema patentnom zahtevu 2, naznačeno time što vezivanje antitela stabilizuje HER3 receptor u njegovom neaktivnom stanju, i naznačeno time što HER3 ligand može istovremeno da se veže za ligand-vezujuće mesto na HER3 receptoru.
4.Izolovano antitelo ili njegov fragment iz patentnog zahteva 3, naznačeno time što vezivanje HER3 liganda za ligand-vezujuće mesto ne može da: a) indukuje konformacionu promenu u HER3 receptoru, u aktivno stanje; ili b) aktivira prenos signala.
5. Izolovano antitelo iz patentnog zahteva 1, naznačeno time što: a)se VH antitela ili njegov fragment vezuju za najmanje jednu od sledećih aminokiselinskih HER3 rezidua: Asn266, Lys267, Leu268, Thr269, Gln271, Glu273, Pro274, Asn275, Pro276, His277, Asn315, Asp571, Pro583, His584, Ala596, Lys597; ili b)se VL antitela ili njegov fragment vezuju za najmanje jednu od sledećih aminokiselinskih HER3 rezidua: Tyr265, Lys267, Leu268, Phe270, Gly582, Pro583, Lys597, Ile600, Lys602, Glu609, Arg611, Pro612, Cys613, His614, Glu615.
6. Izolovano antitelo ili njegov fragment iz patentnog zahteva 1, naznačeno time što izolovano antitelo ili njegov fragment prepoznaje konformacioni epitop prvog HER3 receptora, naznačeno time što: a)vezivanje antitela ili njegovog fragmenta za prvi HER3 receptor u odsustvu liganda za HER3 receptor redukuje ligand-nezavisno formiranje proteinskog kompleksa prvi HER3 receptor-drugi HER3 receptor u ćeliji koja ispoljava prvi HER3 receptor i drugi HER3 receptor; ili b)vezivanje antitela ili njegovog fragmenta za prvi HER3 receptor u prisustvu liganda za HER3 redukuje ligand-zavisno formiranje proteinskog kompleksa prvi HER3 receptor-drugi HER3 receptor u ćeliji koja ispoljava prvi HER3 receptor i drugi HER3 receptor.
7. Izolovano antitelo ili njegov fragment iz patentnog zahteva 6, naznačeno time što: a)u odsustvu liganda za HER3 receptor, antitelo ili njegov fragment stabilizuju prvi HER3 receptor u njegovom neaktivnom stanju tako da prvi HER3 receptor ne može da dimerizuje sa drugim HER3 receptorom i formira proteinski kompleks prvi HER3 receptor-drugi HER3 receptor; ili b)u prisustvu liganda za prvi HER3, antitelo ili njegov fragment stabilizuje prvi HER3 receptor u njegovom neaktivnom stanju tako da HER3 receptor ne može da dimerizuje sa drugim HER3 receptorom i formira proteinski kompleks prvi HER3 receptor- drugi HER3 receptor.
8. Izolovano antitelo ili njegov fragment iz patentnog zahteva 7, naznačeno time što nemogućnost formiranja proteinskog kompleksa prvi HER3 receptor-drugi HER3 receptor sprečava aktivaciju prenosa signala.
9. Izolovano antitelo ili njegov fragment iz patentnog zahteva 1, naznačeno time što: a)vezivanje antitela ili njegovog fragmenta za HER3 receptor u odsustvu liganda za HER3 redukuje ligand-nezavisno formiranje proteinskog kompleksa HER2-HER3 u ćeliji koja ispoljava HER2 i HER3; ili b)vezivanje antitela ili njegovog fragmenta za HER3 receptor u prisustvu liganda za HER3 redukuje ligand-zavisno formiranje proteinskog kompleksa HER2-HER3 u ćeliji koja ispoljava HER2 i HER3.
10. Izolovano antitelo ili njegov fragment iz patentnog zahteva 9, naznačeno time što: a) u odsustvu liganda, antitelo ili njegov fragment stabilizuje HER3 receptor u njegovom neaktivnom stanju tako da HER3 receptor ne može da dimerizuje sa HER2 receptorom i formira proteinski kompleks HER2-HER3; ili b) u prisustvu liganda za HER3 antitelo ili njegov fragment stabilizuje HER3 receptor u njegovom neaktivnom stanju tako da HER3 receptor ne može da dimerizuje sa HER2 receptorom i formira proteinski kompleks HER2-HER3.
11. Izolovano antitelo ili njegov fragment iz patentnog zahteva 10, naznačeno time što nemogućnost formiranja proteinskog kompleksa HER2-HER3 sprečava aktivaciju prenosa signala.
12. Izolovano antitelo ili njegov fragment iz patentnog zahteva 1, naznačeno time što je antitelo izabrano iz grupe koju sačinjavaju monoklonsko antitelo, poliklonsko antitelo, himerno antitelo, humanizovano antitelo i sintetisano antitelo.
13. Izolovano antitelo ili njegov fragment iz patentnih zahteva 3, 6 ili 9, naznačeno time što je ligand za HER3 izabran iz grupe koju sačinjavaju neuregulin 1 (NRG), neuregulin 2, betacelulin, heparin-vezujući faktor rasta epiderma, i epiregulin.
14. Izolovano antitelo ili njegov fragment iz patentnog zahteva 1, naznačeno time što antitelo ili njegov fragment inhibira fosforilaciju HER3 kao što je procenjeno primenom:a) eseja fosforilacije nezavisnog od HER3 liganda ilib) eseja fosforilacije zavisnog od HER3 liganda.
15. Izolovano antitelo ili njegov fragment iz patentnog zahteva 14, naznačeno time što:a) test HER3-ligand nezavisne fosforilacije, koristi HER2 amplifikovane ćelije, gde su HER2 amplifikovane ćelije SK-Br-3 ćelije ib) test HER3-ligand zavisne fosforilacije, koristi stimulisane MCF7 ćelije u prisustvu neuregulina (NRG).
16. Izolovano antitelo ili njegov fragment iz patentnog zahteva 1, naznačeno time što je antitelo ili njegov fragment u unakrsnoj kompeticiji sa ili se vezuje za isti konformacioni epitop kao antitelo MOR9823; MOR9824; MOR9825; MOR9974; MOR10452; MOR10701; MOR10702; MOR10703; MOR10703 N52S; MOR10703 N52G; MOR10703 N52S_S52aN; MOR10703 A50V_N52S; MOR10703 A50V_N52G; MOR10703 S52aT; MOR10701 R55S; MOR10701R55G; MOR10701 R55K; MOR10701 delS56; MOR12609 ili MOR12610.
17. Izolovano antitelo ili njegov fragment iz bilo kog od gore navedenih patentnih zahteva, naznačeno time što je antitelo izabrano iz grupe koju sačinjavaju monoklonsko antitelo, himerno antitelo, jednolančano antitelo, Fab fragment i scFv.
18. Izolovano antitelo ili njegov fragment iz bilo kog od gore navedenih patentnih zahteva, naznačeno time što je antitelo humano.
19. Izolovano antitelo ili njegov fragment iz bilo kog od gore navedenih patentnih zahteva, naznačeno time što u sastav antitela ulazi konstantni region humanog teškog lanca i konstantni region humanog lakog lanca.
20. Izolovano antitelo ili njegov fragment iz bilo kog od gore navedenih patentnih zahteva, naznačeno time što se antitelo ili njegov fragment vezuju i za HER3 čoveka i za HER3 majmuna cynomologus.
21. Izolovano antitelo ili njegov fragment iz bilo kog od gore navedenih patentnih zahteva, naznačeno time što je antitelo ili njegov fragment IgG izotipa.
22. Izolovano antitelo ili njegov fragment iz bilo kog od gore navedenih patentnih zahteva, naznačeno time što antitelo sadrži okvirne sekvence (framework) nastale zamenom aminokiselinama iz odgovarajućih germinativnih sekvenci humanih regiona VH ili VL.
23. Izolovano antitelo ili njegov fragment iz patentnog zahteva 1, u čiji sastav prema računici Kabat ili Chothia ulazi 6 regiona CDR bilo kog od sledećih antitela MOR9823; MOR9824; MOR9825; MOR9974; MOR10452; MOR10701; MOR10702; MOR10703; MOR10703 N52S; MOR10703 N52G; MOR10703 N52S_S52aN; MOR10703 A50V_N52S; MOR10703 A50V_N52G; MOR10703 S52aT; MOR10701 R55S; MOR10701R55G; MOR10701 R55K; MOR10701 delS56; MOR12609 ili MOR12610.
24. U sastav izolovanog antitela ili njegovog fragmenta iz patentnog zahteva 1, ulazi:a) VH koji sadrži sekvencu SEQ ID NO: 15 i VL koji sadrži sekvencu SEQ ID NO: 14, ili aminokiselinsku sekvencu koja im je 97-99% identična; ilib) VH koji sadrži sekvencu SEQ ID NO: 33 i VL koji sadrži sekvencu SEQ ID NO: 32, ili aminokiselinsku sekvencu koja im je 97-99% identična; ilic) VH koji sadrži sekvencu SEQ ID NO: 51 i VL koji sadrži sekvencu SEQ ID NO: 50, ili aminokiselinsku sekvencu koja im je 97-99% identična; ilid) VH koji sadrži sekvencu SEQ ID NO: 69 i VL koji sadrži sekvencu SEQ ID NO: 68, ili aminokiselinsku sekvencu koja im je 97-99% identična; ilie) VH koji sadrži sekvencu SEQ ID NO: 87 i VL koji sadrži sekvencu SEQ ID NO: 86, ili aminokiselinsku sekvencu koja im je 97-99% identična; ilif) VH koji sadrži sekvencu SEQ ID NO: 105 i VL koji sadrži sekvencu SEQ ID NO: 104, ili aminokiselinsku sekvencu koja im je 97-99% identična; ilig) VH koji sadrži sekvencu SEQ ID NO: 123 i VL koji sadrži sekvencu SEQ ID NO: 122, ili aminokiselinsku sekvencu koja im je 97-99% identična; ilih) VH koji sadrži sekvencu SEQ ID NO: 141 i VL koji sadrži sekvencu SEQ ID NO: 140, ili aminokiselinsku sekvencu koja im je 97-99% identična; ilii) VH koji sadrži sekvencu SEQ ID NO: 159 i VL koji sadrži sekvencu SEQ ID NO: 158, ili aminokiselinsku sekvencu koja im je 97-99% identična; ilij) VH koji sadrži sekvencu SEQ ID NO: 177 i VL koji sadrži sekvencu SEQ ID NO: 176, ili aminokiselinsku sekvencu koja im je 97-99% identična; ilik) VH koji sadrži sekvencu SEQ ID NO: 195 i VL koji sadrži sekvencu SEQ ID NO: 194, ili aminokiselinsku sekvencu koja im je 97-99% identična; ilil) VH koji sadrži sekvencu SEQ ID NO: 213 i VL koji sadrži sekvencu SEQ ID NO: 212, ili aminokiselinsku sekvencu koja im je 97-99% identična; ilim) VH koji sadrži sekvencu SEQ ID NO: 231 i VL koji sadrži sekvencu SEQ ID NO: 230, ili aminokiselinsku sekvencu koja im je 97-99% identična; ilin) VH koji sadrži sekvencu SEQ ID NO: 249 i VL koji sadrži sekvencu SEQ ID NO: 248, ili aminokiselinsku sekvencu koja im je 97-99% identična; ilio) VH koji sadrži sekvencu SEQ ID NO: 267 i VL koji sadrži sekvencu SEQ ID NO: 266, ili aminokiselinsku sekvencu koja im je 97-99% identična; ilip) VH koji sadrži sekvencu SEQ ID NO: 285 i VL koji sadrži sekvencu SEQ ID NO: 284, ili aminokiselinsku sekvencu koja im je 97-99% identična; iliq) VH koji sadrži sekvencu SEQ ID NO: 303 i VL koji sadrži sekvencu SEQ ID NO: 302, ili aminokiselinsku sekvencu koja im je 97-99% identična; ilir) VH koji sadrži sekvencu SEQ ID NO: 321 i VL koji sadrži sekvencu SEQ ID NO: 320, ili aminokiselinsku sekvencu koja im je 97-99% identična; ilis) VH koji sadrži sekvencu SEQ ID NO: 339 i VL koji sadrži sekvencu SEQ ID NO: 338, ili aminokiselinsku sekvencu koja im je 97-99% identična; ilit) VH koji sadrži sekvencu SEQ ID NO: 357 i VL koji sadrži sekvencu SEQ ID NO: 356, ili aminokiselinsku sekvencu koja im je 97-99% identična; iliu) VH koji sadrži sekvencu SEQ ID NO: 375 i VL koji sadrži sekvencu SEQ ID NO: 374, ili aminokiselinsku sekvencu koja im je 97-99% identična.
25. Izolovano antitelo ili njegov fragment iz patentnog zahteva 1, sadrži sekvencu varijabilnog domena teškog lanca koja poseduje SEQ ID NO: 493 i/ili sekvencu varijabilnog domena lakog lanca koja poseduje SEQ ID NO: 494.
26. Izolovano antitelo ili njegov fragment iz patentnog zahteva 1, sadrži;a) CDR1 varijabilnog regiona teškog lanca sa sekvencom SEQ ID NO: 2; CDR2 sa sekvencom SEQ ID NO: 3; CDR3 sa sekvencom SEQ ID NO: 4; CDR1 varijabilnog regiona lakog lanca sa sekvencom SEQ ID NO: 5; CDR2 sa sekvencom SEQ ID NO: 6; i CDR3 sa sekvencom SEQ ID NO: 7; ilib) CDR1 varijabilnog regiona teškog lanca sa sekvencom SEQ ID NO: 20; CDR2 sa sekvencom SEQ ID NO: 21; CDR3 sa sekvencom SEQ ID NO: 22; CDR1 varijabilnog regiona lakog lanca sa sekvencom SEQ ID NO: 23; CDR2 sa sekvencom SEQ ID NO: 24; i CDR3 sa sekvencom SEQ ID NO: 25; ilic) CDR1 varijabilnog regiona teškog lanca sa sekvencom SEQ ID NO: 38; CDR2 sa sekvencom SEQ ID NO: 39; CDR3 sa sekvencom SEQ ID NO: 40; CDR1 varijabilnog regiona lakog lanca sa sekvencom SEQ ID NO: 41; CDR2 sa sekvencom SEQ ID NO: 42; i CDR3 sa sekvencom SEQ ID NO: 43; ilid) CDR1 varijabilnog regiona teškog lanca sa sekvencom SEQ ID NO: 56; CDR2 sa sekvencom SEQ ID NO: 57; CDR3 sa sekvencom SEQ ID NO: 58; CDR1 varijabilnog regiona lakog lanca sa sekvencom SEQ ID NO: 59; CDR2 sa sekvencom SEQ ID NO: 60; i CDR3 sa sekvencom SEQ ID NO: 61; ilie) CDR1 varijabilnog regiona teškog lanca sa sekvencom SEQ ID NO: 74; CDR2 sa sekvencom SEQ ID NO: 75; CDR3 sa sekvencom SEQ ID NO: 76; CDR1 varijabilnog regiona lakog lanca sa sekvencom SEQ ID NO: 77; CDR2 sa sekvencom SEQ ID NO: 78; i CDR3 of SEQ ID NO: 79; ilif) CDR1 varijabilnog regiona teškog lanca sa sekvencom SEQ ID NO: 92; CDR2 sa sekvencom SEQ ID NO: 93; CDR3 sa sekvencom SEQ ID NO: 94; CDR1 varijabilnog regiona lakog lanca sa sekvencom SEQ ID NO: 95; CDR2 sa sekvencom SEQ ID NO: 96; i CDR3 of SEQ ID NO: 97; ilig) CDR1 varijabilnog regiona teškog lanca sa sekvencom SEQ ID NO: 110; CDR2 sa sekvencom SEQ ID NO: 111; CDR3 sa sekvencom SEQ ID NO: 112; CDR1 varijabilnog regiona lakog lanca sa sekvencom SEQ ID NO: 113; CDR2 sa sekvencom SEQ ID NO: 114; i CDR3 sa sekvencom SEQ ID NO: 115; ilih) CDR1 varijabilnog regiona teškog lanca sa sekvencom SEQ ID NO: 128; CDR2 sa sekvencom SEQ ID NO: 129; CDR3 sa sekvencom SEQ ID NO: 130; CDR1 varijabilnog regiona lakog lanca sa sekvencom SEQ ID NO: 131; CDR2 sa sekvencom SEQ ID NO: 132; i CDR3 sa sekvencom SEQ ID NO: 133; ilii) CDR1 varijabilnog regiona teškog lanca sa sekvencom SEQ ID NO: 146; CDR2 sa sekvencom SEQ ID NO: 147; CDR3 sa sekvencom SEQ ID NO: 148; CDR1 varijabilnog regiona lakog lanca sa sekvencom SEQ ID NO: 149; CDR2 sa sekvencom SEQ ID NO: 150; i CDR3 sa sekvencom SEQ ID NO: 151; ilij) CDR1 varijabilnog regiona teškog lanca sa sekvencom SEQ ID NO: 164; CDR2 sa sekvencom SEQ ID NO: 165; CDR3 sa sekvencom SEQ ID NO: 166; CDR1 varijabilnog regiona lakog lanca sa sekvencom SEQ ID NO: 167; CDR2 sa sekvencom SEQ ID NO: 168; i CDR3 of SEQ ID NO: 169; ilik) CDR1 varijabilnog regiona teškog lanca sa sekvencom SEQ ID NO: 182; CDR2 sa sekvencom SEQ ID NO: 183; CDR3 sa sekvencom SEQ ID NO: 184; CDR1 varijabilnog regiona lakog lanca sa sekvencom SEQ ID NO: 185; CDR2 sa sekvencom SEQ ID NO: 186; i CDR3 sa sekvencom SEQ ID NO: 187; ilil) CDR1 varijabilnog regiona teškog lanca sa sekvencom SEQ ID NO: 200; CDR2 sa sekvencom SEQ ID NO: 201; CDR3 sa sekvencom SEQ ID NO: 202; CDR1 varijabilnog regiona lakog lanca sa sekvencom SEQ ID NO: 203; CDR2 sa sekvencom SEQ ID NO: 204; i CDR3 sa sekvencom SEQ ID NO: 205; ilim) CDR1 varijabilnog regiona teškog lanca sa sekvencom SEQ ID NO: 218; CDR2 sa sekvencom SEQ ID NO: 219; CDR3 sa sekvencom SEQ ID NO: 220; CDR1 varijabilnog regiona lakog lanca sa sekvencom SEQ ID NO: 221; CDR2 sa sekvencom of SEQ ID NO: 222; i CDR3 sa sekvencom SEQ ID NO: 223; ilin) CDR1 varijabilnog regiona teškog lanca sa sekvencom SEQ ID NO: 236; CDR2 sa sekvencom SEQ ID NO: 237; CDR3 sa sekvencom of SEQ ID NO: 238; CDR1 varijabilnog regiona lakog lanca sa sekvencom SEQ ID NO: 239; CDR2 sa sekvencom SEQ ID NO: 240; i CDR3 sa sekvencom SEQ ID NO: 241; ilio) CDR1 varijabilnog regiona teškog lanca sa sekvencom SEQ ID NO: 254; CDR2 sa sekvencom SEQ ID NO: 255; CDR3 sa sekvencom SEQ ID NO: 256; CDR1 varijabilnog regiona lakog lanca sa sekvencom SEQ ID NO: 257; CDR2 sa sekvencom SEQ ID NO: 258; i CDR3 sa sekvencom SEQ ID NO: 259; ilip) CDR1 varijabilnog regiona teškog lanca sa sekvencom SEQ ID NO: 272; CDR2 sa sekvencom SEQ ID NO: 273; CDR3 sa sekvencom SEQ ID NO: 274; CDR1 varijabilnog regiona lakog lanca sa sekvencom SEQ ID NO: 275; CDR2 sa sekvencom SEQ ID NO: 276; i CDR3 sa sekvencom SEQ ID NO: 277; iliq) CDR1 varijabilnog regiona teškog lanca sa sekvencom SEQ ID NO: 290; CDR2 sa sekvencom SEQ ID NO: 291; CDR3 sa sekvencom SEQ ID NO: 292; CDR1 varijabilnog regiona lakog lanca sa sekvencom SEQ ID NO: 293; CDR2 sa sekvencom SEQ ID NO: 294; i CDR3 sa sekvencom SEQ ID NO: 295; ilir) CDR1 varijabilnog regiona teškog lanca sa sekvencom SEQ ID NO: 308; CDR2 sa sekvencom SEQ ID NO: 309; CDR3 sa sekvencom SEQ ID NO: 310; CDR1 varijabilnog regiona lakog lanca sa sekvencom SEQ ID NO: 311; CDR2 sa sekvencom SEQ ID NO: 312; i CDR3 sa sekvencom SEQ ID NO: 313; ilis) CDR1 varijabilnog regiona teškog lanca sa sekvencom SEQ ID NO: 326; CDR2 sa sekvencom SEQ ID NO: 327; CDR3 sa sekvencom SEQ ID NO: 328; CDR1 varijabilnog regiona lakog lanca sa sekvencom SEQ ID NO: 329; CDR2 sa sekvencom SEQ ID NO: 330; i CDR3 sa sekvencom SEQ ID NO: 331; ilit) CDR1 varijabilnog regiona teškog lanca sa sekvencom SEQ ID NO: 344; CDR2 sa sekvencom SEQ ID NO: 345; CDR3 sa sekvencom SEQ ID NO: 346; CDR1 varijabilnog regiona lakog lanca sa sekvencom SEQ ID NO: 347; CDR2 sa sekvencom SEQ ID NO: 348; i CDR3 sa sekvencom SEQ ID NO: 349; iliu) CDR1 varijabilnog regiona teškog lanca sa sekvencom SEQ ID NO: 362; CDR2 sa sekvencom SEQ ID NO: 363; CDR3 sa sekvencom SEQ ID NO: 364; CDR1 varijabilnog regiona lakog lanca sa sekvencom SEQ ID NO: 365; CDR2 sa sekvencom SEQ ID NO: 366; i CDR3 sa sekvencom SEQ ID NO: 367.
27. Fragment antitela iz bilo kog prethodnog patentnog zahteva, izabran je iz grupe koja se sastoji od; Fab, F(ab2)’, F(ab)2’, scFv, VHH, VH, VL, d antitela .
28. Farmaceutska kompozicija se sastoji od antitela ili njegovog fragmenta izabranog iz bilo kog od prethodnih patentnih zahteva i farmaceutski prihvatljivog nosača.
29. Farmaceutska kompozicija iz patentnog zahteva 28, osim toga sadrži dodatni terapijski agens.
30. Farmaceutska kompozicija iz patentnog zahteva 29, naznačeno time što je dodatni terapijski agens izabran iz grupe koja sadrži inhibitor HER1, inhibitor HER2, inhibitor HER3, inhibitor HER4, inhibitor mTOR i inhibitor PI3 kinaze.
31. Farmaceutska kompozicija iz patentnog zahteva 30, naznačeno time što je:a) kada je dodatni terapijski agens inhibitor HER1, inhibitor HER1 je izabran iz grupe u čiji sastav ulaze Matuzumab (EMD72000), Erbitux®/Cetuximab, Vectibix® /Panitumumab, monoklonskog antitela 806, Nimotuzumab, Iressa® /Gefitinib, CI-1033 (PD183805), Lapatinib (GW-572016), Tykerb® /Lapatinib Ditosylate, Tarceva® / Erlotinib HCL (OSI-774), PKI-166, i Tovok®; inhibitor HER2 je izabran iz grupe u čiji sastav ulaze Pertuzumab, Trastuzumab, MM-111, neratinib, lapatinib ili lapatinib ditosylate /Tykerb®; inhibitor HER3 je izabran iz grupe u čiji sastav ulaze MM-121, MM-111, IB4C3, 2DID12 (U3 Pharma AG), AMG888 (Amgen), AV-203(Aveo), MEHD7945A (Genentech) i mali molekuli koji inhibiraju HER3; i inhibitor HER4;b) kada je dodatni terapijski agens inhibitor mTOR, inhibitor mTOR je izabran iz grupe u čiji sastav ulaze Temsirolimus/Torisel®, ridaforolimus / Deforolimus, AP23573, MK8669, everolimus /Affinitor® ;c) kada je dodatni terapijski agens inhibitor PI3 kinaze, inhibitor PI3 kinaze je izabran iz grupe u čiji sastav ulaze GDC 0941, BEZ235, BMK120 i BYL719.
32. Antitelo ili njegov fragment prema bilo kom od patentnih zahteva od 1 do 27 ili kompozicija prema bilo kom od patentnih zahteva od 28 do 31 za upotrebu u svojstvu leka.
33. Antitelo ili njegov fragment prema bilo kom od patentnih zahteva od 1 do 27 ili kompozicija prema bilo kom od patentnih zahteva od 28 do 31 za upotrebu u lečenju kancera.
34. Antitelo ili njegov fragment prema bilo kom od patentnih zahteva od 1 do 27 ili kompozicija prema bilo kom od patentnih zahteva od 28 do 31 za upotrebu u lečenju kancera prema patentnom zahtevu 33, naznačeno time što je kancer posredovan HER3 signalnim putem.
35. Antitelo ili njegov fragment prema bilo kom od patentnih zahteva od 1 do 27 ili kompozicija prema bilo kom od patentnih zahteva od 28 do 31 za upotrebu u lečenju kancera prema patentnom zahtevu 34, naznačeno time što je kancer izabran iz grupe u kojoj se nalaze kancer dojke, kolorektalni kancer, kancer pluća, multipli mijelom, kancer jajnika, kancer jetre, kancer želuca, kancer pankreasa, kancer prostate, akutna mijeloidna leukemija, hronična mijeloidna leukemija, osteosarkom, karcinom skvamoznih ćelija, tumori ovojnice perifernog nerva, švanom, kancer glave i vrata, kancer mokraćne bešike, kancer jednjaka, glioblastom, sarkom svetlih ćelija mekog tkiva, maligni mezoteliom, neurofibromatoza, kancer bubrega, i melanom.
MEP-2017-65A 2010-08-20 2011-08-22 Antitela za receptor 3 faktora rasta epiderma (her3) ME02637B (me)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US37540810P 2010-08-20 2010-08-20
PCT/EP2011/064407 WO2012022814A1 (en) 2010-08-20 2011-08-22 Antibodies for epidermal growth factor receptor 3 (her3)
EP11746252.3A EP2606070B1 (en) 2010-08-20 2011-08-22 Antibodies for epidermal growth factor receptor 3 (her3)

Publications (1)

Publication Number Publication Date
ME02637B true ME02637B (me) 2017-06-20

Family

ID=44630597

Family Applications (1)

Application Number Title Priority Date Filing Date
MEP-2017-65A ME02637B (me) 2010-08-20 2011-08-22 Antitela za receptor 3 faktora rasta epiderma (her3)

Country Status (39)

Country Link
US (3) US8735551B2 (me)
EP (1) EP2606070B1 (me)
JP (4) JP6057896B2 (me)
KR (1) KR102027011B1 (me)
CN (2) CN103080134B (me)
AU (1) AU2011290672B2 (me)
BR (1) BR112013004012B1 (me)
CA (1) CA2806637C (me)
CL (2) CL2013000459A1 (me)
CO (1) CO6680688A2 (me)
CR (1) CR20130071A (me)
CU (1) CU24094B1 (me)
CY (1) CY1118761T1 (me)
DK (1) DK2606070T3 (me)
DO (1) DOP2013000044A (me)
EA (1) EA036314B1 (me)
ES (1) ES2620255T3 (me)
GE (1) GEP201706605B (me)
GT (1) GT201300046A (me)
HR (1) HRP20170462T1 (me)
HU (1) HUE031855T2 (me)
IL (2) IL226712B (me)
LT (1) LT2606070T (me)
MA (1) MA34524B1 (me)
ME (1) ME02637B (me)
MX (1) MX2013002046A (me)
MY (1) MY162825A (me)
NI (1) NI201300023A (me)
NZ (1) NZ607337A (me)
PE (1) PE20140230A1 (me)
PH (1) PH12013500333A1 (me)
PL (1) PL2606070T4 (me)
PT (1) PT2606070T (me)
RS (1) RS55930B1 (me)
SG (1) SG187908A1 (me)
SI (1) SI2606070T1 (me)
SM (1) SMT201700217T1 (me)
UA (1) UA114883C2 (me)
WO (1) WO2012022814A1 (me)

Families Citing this family (79)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PH12012501157A1 (en) 2009-12-22 2012-10-29 Roche Glycart Ag Anti-her3 antibodies and uses thereof
ME02637B (me) * 2010-08-20 2017-06-20 Novartis Ag Antitela za receptor 3 faktora rasta epiderma (her3)
WO2012059857A2 (en) 2010-11-01 2012-05-10 Symphogen A/S Pan-her antibody composition
ITRM20100577A1 (it) * 2010-11-02 2012-05-03 Takis Srl Immunoterapia contro il recettore erbb-3
MX336197B (es) * 2011-04-19 2016-01-11 Merrimack Pharmaceuticals Inc Anicuerpos anti-igf-1r y anti-erbb3 monoespecificos y biespecificos.
WO2012176779A1 (ja) * 2011-06-20 2012-12-27 協和発酵キリン株式会社 抗ｅｒｂＢ３抗体
US9273143B2 (en) 2011-09-30 2016-03-01 Regeneron Pharmaceuticals, Inc. Methods and compositions comprising a combination of an anti-ErbB3 antibody and an anti-EGFR antibody
WO2013048883A2 (en) 2011-09-30 2013-04-04 Regeneron Pharmaceuticals, Inc. Anti-erbb3 antibodies and uses thereof
GB2504139B (en) * 2012-07-20 2014-12-31 Argen X Bv Antibodies to highly conserved targets produced by the immunisation of Camelidae species
WO2013071058A1 (en) * 2011-11-09 2013-05-16 The Uab Research Foundation Her3 antibodies and uses thereof
CN108424456B (zh) 2011-11-23 2022-04-26 医学免疫有限责任公司 特异于her3的结合分子及其用途
EP2788382A2 (en) * 2011-12-05 2014-10-15 Novartis AG Antibodies for epidermal growth factor receptor 3 (her3) directed to domain ii of her3
CN108341873B (zh) * 2011-12-05 2022-03-25 诺华股份有限公司 表皮生长因子受体3(her3)的抗体
US20150037336A1 (en) * 2012-02-22 2015-02-05 U3 Pharma Gmbh Combination of hb-egf binding protein and egfr inhibitor
WO2014018747A2 (en) 2012-07-26 2014-01-30 Momenta Pharmaceuticals, Inc. Glycoproteins with anti-inflammatory properties
ES2870004T3 (es) * 2012-08-21 2021-10-26 Janssen Pharmaceutica Nv Anticuerpos contra la risperidona y uso de los mismos
JP2015534997A (ja) * 2012-10-25 2015-12-07 ソレント・セラピューティクス・インコーポレイテッドＳｏｒｒｅｎｔｏ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． ＥｒｂＢ３と結合する抗原結合タンパク質
CN104755500B (zh) 2012-11-08 2020-10-02 霍夫曼-拉罗奇有限公司 结合HER3 β-发夹的HER3抗原结合蛋白
CN104755499B (zh) * 2012-11-08 2020-10-02 霍夫曼-拉罗奇有限公司 结合HER3 β-发夹和HER4 β-发夹的抗HER3/HER4抗原结合蛋白
CN102993305B (zh) * 2012-11-16 2015-05-13 上海赛伦生物技术有限公司 人源抗人表皮生长因子受体抗体及其编码基因与应用
AR094403A1 (es) 2013-01-11 2015-07-29 Hoffmann La Roche Terapia de combinación de anticuerpos anti-her3
US20160228589A1 (en) * 2013-09-18 2016-08-11 Sloan-Kettering Institute For Cancer Research Methods and compositions for imaging disorders using polyspecific agents
US11305012B2 (en) 2013-09-24 2022-04-19 Medimmune, Llc Binding molecules specific for HER3 and uses thereof
EP3049442A4 (en) 2013-09-26 2017-06-28 Costim Pharmaceuticals Inc. Methods for treating hematologic cancers
WO2015066543A1 (en) * 2013-11-01 2015-05-07 Board Of Regents, The University Of Texas System Targeting her2 and her3 with bispecific antibodies in cancerous cells
UA122479C2 (uk) 2014-01-24 2020-11-25 Дана-Фарбер Кенсер Інстітьют, Інк. Виділена молекула антитіла, яка зв’язується з людським білком програмованої смерті-1 (pd-1)
PL3099717T3 (pl) 2014-01-31 2019-10-31 Novartis Ag Cząsteczki przeciwciała dla TIM-3 i ich zastosowanie
DK3805268T3 (da) 2014-02-28 2025-01-20 Merus Nv Antistof, der binder erbb-2 og erbb-3
CA2941030C (en) 2014-02-28 2025-05-13 Merus N.V. ANTIBODIES THAT BIND TO EGFR AND ERBB3
EA201691765A1 (ru) 2014-03-14 2016-12-30 Новартис Аг Молекулы антител против lag-3 и их применения
US10745490B2 (en) 2014-04-11 2020-08-18 Celldex Therapeutics, Inc. Anti-ErbB antibodies and methods of use thereof
FR3020063A1 (fr) 2014-04-16 2015-10-23 Gamamabs Pharma Anticorps humain anti-her4
JP6695812B2 (ja) * 2014-05-14 2020-05-20 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト Ｈｅｒ３のベータヘアピン及びｈｅｒ２のドメインｉｉに結合するｈｅｒ３／ｈｅｒ２二重特異性抗体
KR20160144465A (ko) * 2014-05-14 2016-12-16 에프. 호프만-라 로슈 아게 Her3의 베타-헤어핀에 결합하는 항-her3 항체
US20170291956A1 (en) 2014-07-16 2017-10-12 David Livingston HER3 Inhibition in Low-grade Serous Ovarian Cancers
CN105367657B (zh) * 2014-08-14 2019-09-13 上海生物制品研究所有限责任公司 抗her3抗体、其制法及其应用
EP3191126B1 (en) 2014-09-13 2020-05-13 Novartis AG Combination therapies of alk inhibitors
KR20170066546A (ko) 2014-10-03 2017-06-14 노파르티스 아게 조합 요법
MA41044A (fr) 2014-10-08 2017-08-15 Novartis Ag Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer
SG11201702401RA (en) 2014-10-14 2017-04-27 Novartis Ag Antibody molecules to pd-l1 and uses thereof
EP3229803B1 (en) * 2014-12-12 2020-01-29 Massachusetts General Hospital Treatment of breast cancer brain metastases
TWI706958B (zh) 2015-03-10 2020-10-11 美商艾杜諾生物科技公司 活化「干擾素基因刺激因子」依賴性訊息傳導之組合物及方法
JP2018524373A (ja) * 2015-07-15 2018-08-30 ザイムワークス，インコーポレイテッド 薬物がコンジュゲートされた二重特異性抗原結合コンストラクト
TW201716439A (zh) 2015-07-20 2017-05-16 美國禮來大藥廠 Ｈｅｒ３抗體
US20180207273A1 (en) 2015-07-29 2018-07-26 Novartis Ag Combination therapies comprising antibody molecules to tim-3
EP3328418A1 (en) 2015-07-29 2018-06-06 Novartis AG Combination therapies comprising antibody molecules to pd-1
US20180340025A1 (en) 2015-07-29 2018-11-29 Novartis Ag Combination therapies comprising antibody molecules to lag-3
EP3334762A1 (en) 2015-08-14 2018-06-20 Allergan, Inc. Heavy chain only antibodies to pdgf
JP7296728B2 (ja) 2015-10-23 2023-06-23 メルス ナムローゼ フェンノートシャップ 癌の成長を抑制する結合分子
PT3370768T (pt) 2015-11-03 2022-04-21 Janssen Biotech Inc Anticorpos que se ligam especificamente ao pd-1 e seus usos
JP6629581B2 (ja) * 2015-11-30 2020-01-15 サントリーホールディングス株式会社 ヒドロキシチロソール含有茶飲料
US10689458B2 (en) 2015-11-30 2020-06-23 Pfizer Inc. Site specific HER2 antibody drug conjugates
KR101746152B1 (ko) * 2015-12-07 2017-06-13 주식회사 이수앱지스 ＥｒｂＢ3에 특이적으로 결합하는 항체 및 그의 용도
MA43416A (fr) 2015-12-11 2018-10-17 Regeneron Pharma Méthodes pour ralentir ou empêcher la croissance de tumeurs résistantes au blocage de l'egfr et/ou d'erbb3
CN108495651A (zh) 2015-12-17 2018-09-04 诺华股份有限公司 抗pd-1的抗体分子及其用途
WO2017160990A1 (en) 2016-03-15 2017-09-21 Merrimack Pharmaceuticals, Inc. Methods for treating er+, her2-, hrg+ breast cancer using combination therapies comprising an anti-erbb3 antibody
EP3507367A4 (en) 2016-07-05 2020-03-25 Aduro BioTech, Inc. CYCLIC DINUCLEOTID COMPOUNDS WITH INCLUDED NUCLEIC ACIDS AND USES THEREOF
US12667557B2 (en) 2017-02-28 2026-06-30 Daiichi Sankyo Company, Limited Method for treating EGFR-TKI-resistant non-small cell lung cancer by administration of anti-HER3 antibody-drug conjugate
JP7737220B2 (ja) 2017-03-31 2025-09-10 メルス ナムローゼ フェンノートシャップ ＮＲＧ１融合遺伝子を有する細胞の処置における使用のためのＥｒｂＢ－２及びＥｒｂＢ３結合二重特異性抗体
MX2019011658A (es) 2017-03-31 2019-11-18 Merus Nv Agente que se dirige al receptor 2 del factor de crecimiento epidermico humano (erbb-2) y anticuerpo biespecifico con sitios de union a antigeno que se unen a un epitopo sobre una parte extracelular de erbb-2 y el receptor 3 del factor de crecimiento epidermico humano (erbb-3), para el tratamiento de un individuo con un tumor positivo para erbb-2, erbb-2/erbb-3.
UY37695A (es) 2017-04-28 2018-11-30 Novartis Ag Compuesto dinucleótido cíclico bis 2’-5’-rr-(3’f-a)(3’f-a) y usos del mismo
EP3625264B9 (en) 2017-05-17 2023-10-25 Merus N.V. Combination of an erbb-2/erbb-3 bispecific antibody with endocrine therapy for breast cancer
US20200172628A1 (en) 2017-06-22 2020-06-04 Novartis Ag Antibody molecules to cd73 and uses thereof
RS66708B9 (sr) 2017-08-09 2025-08-29 Merus Nv Antitela koja se vezuju za egfr i cmet
TWI808092B (zh) 2017-08-30 2023-07-11 中國大陸商北京軒義醫藥科技有限公司 作為干擾素基因調節劑之刺激劑的環狀二核苷酸
MX2020004531A (es) 2017-11-03 2020-08-03 Aurigene Discovery Tech Ltd Inhibidores dobles de tim-3 y las vias de pd-1.
EP3706798A1 (en) 2017-11-06 2020-09-16 Aurigene Discovery Technologies Limited Conjoint therapies for immunomodulation
US12398209B2 (en) 2018-01-22 2025-08-26 Janssen Biotech, Inc. Methods of treating cancers with antagonistic anti-PD-1 antibodies
EP3768259A4 (en) 2018-03-14 2022-04-06 Aurigene Discovery Technologies Limited METHODS OF MODULATION OF TIGIT AND PD-1 SIGNALING PATHWAYS USING 1,2,4-OXADIAZOLE COMPOUNDS
WO2019185164A1 (en) * 2018-03-29 2019-10-03 Hummingbird Bioscience Holdings Pte. Ltd. Her3 antigen-binding molecules
UY38247A (es) 2018-05-30 2019-12-31 Novartis Ag Anticuerpos frente a entpd2, terapias de combinación y métodos de uso de los anticuerpos y las terapias de combinación
CA3112043A1 (en) 2018-09-10 2020-03-19 Mirati Therapeutics, Inc. Combination therapies
WO2020059772A1 (ja) 2018-09-20 2020-03-26 第一三共株式会社 抗ｈｅｒ３抗体－薬物コンジュゲート投与によるｈｅｒ３変異がんの治療
CN110760003A (zh) * 2019-09-10 2020-02-07 广东药科大学 一种抗her3单链抗体的制备方法
JP2022548881A (ja) 2019-09-18 2022-11-22 ノバルティス アーゲー Ｅｎｔｐｄ２抗体、組合せ療法並びに抗体及び組合せ療法を使用する方法
KR20230012560A (ko) * 2020-05-19 2023-01-26 모멘타 파머슈티컬스 인코포레이티드 과시알화된 IgG의 제조 및 정제
EP4355787A4 (en) * 2021-06-15 2025-04-30 Beijing Sinotau Bio-Pharmaceuticals Technology Co., Ltd. Anti-her3 antibody, antibody drug conjugate containing the same, and use thereof
CN113788895B (zh) * 2021-10-14 2023-09-15 陕西健吉跃生物科技有限公司 一种兔多克隆抗体及其制备方法和应用
JPWO2024248123A1 (me) 2023-06-02 2024-12-05

Family Cites Families (185)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4458066A (en) 1980-02-29 1984-07-03 University Patents, Inc. Process for preparing polynucleotides
EP0092918B1 (en) 1982-04-22 1988-10-19 Imperial Chemical Industries Plc Continuous release formulations
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
CA1247080A (en) 1983-03-08 1988-12-20 Commonwealth Serum Laboratories Commission Antigenically active amino acid sequences
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
DE3572982D1 (en) 1984-03-06 1989-10-19 Takeda Chemical Industries Ltd Chemically modified lymphokine and production thereof
US5128326A (en) 1984-12-06 1992-07-07 Biomatrix, Inc. Drug delivery systems based on hyaluronans derivatives thereof and their salts and methods of producing same
US5374548A (en) 1986-05-02 1994-12-20 Genentech, Inc. Methods and compositions for the attachment of proteins to liposomes using a glycophospholipid anchor
MX9203291A (es) 1985-06-26 1992-08-01 Liposome Co Inc Metodo para acoplamiento de liposomas.
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US5260203A (en) 1986-09-02 1993-11-09 Enzon, Inc. Single polypeptide chain binding molecules
US4881175A (en) 1986-09-02 1989-11-14 Genex Corporation Computer based system and method for determining and displaying possible chemical structures for converting double- or multiple-chain polypeptides to single-chain polypeptides
JP3101690B2 (ja) 1987-03-18 2000-10-23 エス・ビィ・２・インコーポレイテッド 変性抗体の、または変性抗体に関する改良
US5013653A (en) 1987-03-20 1991-05-07 Creative Biomolecules, Inc. Product and process for introduction of a hinge region into a fusion protein to facilitate cleavage
JPH02500329A (ja) 1987-05-21 1990-02-08 クリエイテイブ・バイオマリキユールズ・インコーポレーテツド ターゲット化多機能蛋白質
US5091513A (en) 1987-05-21 1992-02-25 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
US5258498A (en) 1987-05-21 1993-11-02 Creative Biomolecules, Inc. Polypeptide linkers for production of biosynthetic proteins
US5132405A (en) 1987-05-21 1992-07-21 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
US4880078A (en) 1987-06-29 1989-11-14 Honda Giken Kogyo Kabushiki Kaisha Exhaust muffler
US5677425A (en) 1987-09-04 1997-10-14 Celltech Therapeutics Limited Recombinant antibody
US5336603A (en) 1987-10-02 1994-08-09 Genentech, Inc. CD4 adheson variants
US5476996A (en) 1988-06-14 1995-12-19 Lidak Pharmaceuticals Human immune system in non-human animal
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
KR900005995A (ko) 1988-10-31 1990-05-07 우메모또 요시마사 변형 인터류킨-2 및 그의 제조방법
FI903489A7 (fi) 1988-11-11 1990-07-10 Medical Res Council Yhden osan sisältävät ligandit, näitä ligandeja sisältävät reseptorit, menetelmiä niiden valmistamiseksi sekä ligandien ja reseptorien käytt ö
EP0401384B1 (en) 1988-12-22 1996-03-13 Kirin-Amgen, Inc. Chemically modified granulocyte colony stimulating factor
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5108921A (en) 1989-04-03 1992-04-28 Purdue Research Foundation Method for enhanced transmembrane transport of exogenous molecules
ATE92107T1 (de) 1989-04-29 1993-08-15 Delta Biotechnology Ltd N-terminale fragmente von menschliches serumalbumin enthaltenden fusionsproteinen.
US6291158B1 (en) 1989-05-16 2001-09-18 Scripps Research Institute Method for tapping the immunological repertoire
US5112946A (en) 1989-07-06 1992-05-12 Repligen Corporation Modified pf4 compositions and methods of use
FR2650598B1 (fr) 1989-08-03 1994-06-03 Rhone Poulenc Sante Derives de l'albumine a fonction therapeutique
AU6430190A (en) 1989-10-10 1991-05-16 Pitman-Moore, Inc. Sustained release composition for macromolecular proteins
WO1991006570A1 (en) 1989-10-25 1991-05-16 The University Of Melbourne HYBRID Fc RECEPTOR MOLECULES
CA2071867A1 (en) 1989-11-06 1991-05-07 Edith Mathiowitz Method for producing protein microspheres
US5183884A (en) 1989-12-01 1993-02-02 United States Of America Dna segment encoding a gene for a receptor related to the epidermal growth factor receptor
US6673986B1 (en) 1990-01-12 2004-01-06 Abgenix, Inc. Generation of xenogeneic antibodies
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
EP1690935A3 (en) 1990-01-12 2008-07-30 Abgenix, Inc. Generation of xenogeneic antibodies
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
US5349053A (en) 1990-06-01 1994-09-20 Protein Design Labs, Inc. Chimeric ligand/immunoglobulin molecules and their uses
US6172197B1 (en) 1991-07-10 2001-01-09 Medical Research Council Methods for producing members of specific binding pairs
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US6300129B1 (en) 1990-08-29 2001-10-09 Genpharm International Transgenic non-human animals for producing heterologous antibodies
US6255458B1 (en) 1990-08-29 2001-07-03 Genpharm International High affinity human antibodies and human antibodies against digoxin
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
ES2246502T3 (es) 1990-08-29 2006-02-16 Genpharm International, Inc. Animales no humanos transgenicos capaces de producir anticuerpos heterologos.
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5877397A (en) 1990-08-29 1999-03-02 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5874299A (en) 1990-08-29 1999-02-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5789650A (en) 1990-08-29 1998-08-04 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
ATE145428T1 (de) 1990-12-14 1996-12-15 Cell Genesys Inc Chimärische ketten zur transduktion von rezeptorverbundenen signalwegen
JPH06507404A (ja) 1991-05-01 1994-08-25 ヘンリー　エム．ジャクソン　ファウンデイション　フォー　ザ　アドバンスメント　オブ　ミリタリー　メディスン 感染性の呼吸性疾患の治療方法
PT1024191E (pt) 1991-12-02 2008-12-22 Medical Res Council Produção de auto-anticorpos a partir de reportórios de segmentos de anticorpo e exibidos em fagos
DE69233408T2 (de) 1991-12-02 2005-09-22 Cambridge Antibody Technology Ltd., Melbourn Herstellung von Antikörpern auf Phagenoberflächen ausgehend von Antikörpersegmentbibliotheken.
JPH07503132A (ja) 1991-12-17 1995-04-06 ジェンファーム　インターナショナル，インコーポレイティド 異種抗体を産生することができるトランスジェニック非ヒト動物
US5622929A (en) 1992-01-23 1997-04-22 Bristol-Myers Squibb Company Thioether conjugates
FR2686901A1 (fr) 1992-01-31 1993-08-06 Rhone Poulenc Rorer Sa Nouveaux polypeptides antithrombotiques, leur preparation et compositions pharmaceutiques les contenant.
FR2686899B1 (fr) 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
US5714350A (en) 1992-03-09 1998-02-03 Protein Design Labs, Inc. Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region
US5912015A (en) 1992-03-12 1999-06-15 Alkermes Controlled Therapeutics, Inc. Modulated release from biocompatible polymers
US5447851B1 (en) 1992-04-02 1999-07-06 Univ Texas System Board Of Dna encoding a chimeric polypeptide comprising the extracellular domain of tnf receptor fused to igg vectors and host cells
AU4116793A (en) 1992-04-24 1993-11-29 Board Of Regents, The University Of Texas System Recombinant production of immunoglobulin-like domains in prokaryotic cells
DE69334275D1 (de) 1992-08-21 2009-05-20 Univ Bruxelles Immunoglobuline ohne Leichtkette
US6765087B1 (en) 1992-08-21 2004-07-20 Vrije Universiteit Brussel Immunoglobulins devoid of light chains
US5958708A (en) 1992-09-25 1999-09-28 Novartis Corporation Reshaped monoclonal antibodies against an immunoglobulin isotype
CA2103323A1 (en) 1992-11-24 1994-05-25 Gregory D. Plowman Her4 human receptor tyrosine kinase
US5934272A (en) 1993-01-29 1999-08-10 Aradigm Corporation Device and method of creating aerosolized mist of respiratory drug
AU6819494A (en) 1993-04-26 1994-11-21 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
WO1994025591A1 (en) 1993-04-29 1994-11-10 Unilever N.V. PRODUCTION OF ANTIBODIES OR (FUNCTIONALIZED) FRAGMENTS THEREOF DERIVED FROM HEAVY CHAIN IMMUNOGLOBULINS OF $i(CAMELIDAE)
AU691811B2 (en) 1993-06-16 1998-05-28 Celltech Therapeutics Limited Antibodies
SE9400088D0 (sv) 1994-01-14 1994-01-14 Kabi Pharmacia Ab Bacterial receptor structures
US5837458A (en) 1994-02-17 1998-11-17 Maxygen, Inc. Methods and compositions for cellular and metabolic engineering
US5834252A (en) 1995-04-18 1998-11-10 Glaxo Group Limited End-complementary polymerase reaction
US5605793A (en) 1994-02-17 1997-02-25 Affymax Technologies N.V. Methods for in vitro recombination
CZ25697A3 (en) 1994-07-29 1997-09-17 Smithkline Beecham Plc Novel compounds
US6132764A (en) 1994-08-05 2000-10-17 Targesome, Inc. Targeted polymerized liposome diagnostic and treatment agents
ATE252894T1 (de) 1995-01-05 2003-11-15 Univ Michigan Oberflächen-modifizierte nanopartikel und verfahren für ihre herstellung und verwendung
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
US6019968A (en) 1995-04-14 2000-02-01 Inhale Therapeutic Systems, Inc. Dispersible antibody compositions and methods for their preparation and use
US6121022A (en) 1995-04-14 2000-09-19 Genentech, Inc. Altered polypeptides with increased half-life
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
AU710347B2 (en) 1995-08-31 1999-09-16 Alkermes Controlled Therapeutics, Inc. Composition for sustained release of an agent
US5985320A (en) 1996-03-04 1999-11-16 The Penn State Research Foundation Materials and methods for enhancing cellular internalization
CA2249195A1 (en) 1996-03-18 1997-09-25 Board Of Regents, The University Of Texas System Immunoglobin-like domains with increased half lives
US5874064A (en) 1996-05-24 1999-02-23 Massachusetts Institute Of Technology Aerodynamically light particles for pulmonary drug delivery
US5855913A (en) 1997-01-16 1999-01-05 Massachusetts Instite Of Technology Particles incorporating surfactants for pulmonary drug delivery
US5985309A (en) 1996-05-24 1999-11-16 Massachusetts Institute Of Technology Preparation of particles for inhalation
US6056973A (en) 1996-10-11 2000-05-02 Sequus Pharmaceuticals, Inc. Therapeutic liposome composition and method of preparation
WO1998023289A1 (en) 1996-11-27 1998-06-04 The General Hospital Corporation MODULATION OF IgG BINDING TO FcRn
DE69732306T2 (de) 1997-01-16 2006-01-12 Massachusetts Institute Of Technology, Cambridge Zubereitung von partikelhaltigen arzneimitteln zur inhalation
US6136558A (en) 1997-02-10 2000-10-24 Genentech, Inc. Heregulin variants
US6277375B1 (en) 1997-03-03 2001-08-21 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
EP0983303B1 (en) 1997-05-21 2006-03-08 Biovation Limited Method for the production of non-immunogenic proteins
AU736707B2 (en) 1997-06-11 2001-08-02 Anaphore, Inc. Trimerising module
JP3614866B2 (ja) 1997-06-12 2005-01-26 リサーチ コーポレイション テクノロジーズ，インコーポレイティド 人工抗体ポリペプチド
US5989463A (en) 1997-09-24 1999-11-23 Alkermes Controlled Therapeutics, Inc. Methods for fabricating polymer-based controlled release devices
DE19742706B4 (de) 1997-09-26 2013-07-25 Pieris Proteolab Ag Lipocalinmuteine
AU9805398A (en) 1997-10-15 1999-05-03 Children's Medical Center Corporation Novel human egf receptors and use thereof
GB9722131D0 (en) 1997-10-20 1997-12-17 Medical Res Council Method
SE512663C2 (sv) 1997-10-23 2000-04-17 Biogram Ab Inkapslingsförfarande för aktiv substans i en bionedbrytbar polymer
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
JP4334141B2 (ja) 1998-04-20 2009-09-30 グリカート バイオテクノロジー アクチェンゲゼルシャフト 抗体依存性細胞傷害性を改善するための抗体のグリコシル化操作
ES2198922T3 (es) 1998-06-24 2004-02-01 Advanced Inhalation Research, Inc. Particulas porosas grandes emitadas por un inhalador.
US6818418B1 (en) 1998-12-10 2004-11-16 Compound Therapeutics, Inc. Protein scaffolds for antibody mimics and other binding proteins
HUP0104865A3 (en) 1999-01-15 2004-07-28 Genentech Inc Polypeptide variants with altered effector function
EP2275540B1 (en) 1999-04-09 2016-03-23 Kyowa Hakko Kirin Co., Ltd. Method for controlling the activity of immunologically functional molecule
DE19932688B4 (de) 1999-07-13 2009-10-08 Scil Proteins Gmbh Design von Beta-Faltblatt-Proteinen des gamma-II-kristallins antikörperähnlichen
CA2347973C (en) 1999-07-20 2010-06-22 Morphosys Ag Novel methods for displaying (poly)peptides/proteins on bacteriophage particles via disulfide bonds
NZ517202A (en) 1999-08-24 2004-05-28 Medarex Inc Human CTLA-4 antibodies and their uses
US6926898B2 (en) 2000-04-12 2005-08-09 Human Genome Sciences, Inc. Albumin fusion proteins
CA2441903C (en) 2000-05-26 2012-07-31 National Research Council Of Canada Single-domain brain-targeting antibody fragments derived from llama antibodies
DE60131456T2 (de) 2000-11-30 2008-07-10 Medarex, Inc., Milpitas Transchromosomale transgen-nagetiere zur herstellung von humanen antikörpern
CN1551767A (zh) 2001-02-19 2004-12-01 ��˹��ŵ�� 癌症的治疗
US20040175756A1 (en) 2001-04-26 2004-09-09 Avidia Research Institute Methods for using combinatorial libraries of monomer domains
US20050053973A1 (en) 2001-04-26 2005-03-10 Avidia Research Institute Novel proteins with targeted binding
US20050048512A1 (en) 2001-04-26 2005-03-03 Avidia Research Institute Combinatorial libraries of monomer domains
JP2004532038A (ja) 2001-05-17 2004-10-21 ディヴァーサ コーポレイション 新規抗原結合分子の治療、診断、予防、酵素、産業ならびに農業各分野への応用とそのための新規抗原結合分子の作製とスクリーニングの方法
JP4303105B2 (ja) 2001-06-28 2009-07-29 ドマンティス リミテッド 二重特異性リガンドとその利用
ITMI20011483A1 (it) 2001-07-11 2003-01-11 Res & Innovation Soc Coop A R Uso di composti come antagonisti funzionali ai recettori centrali deicannabinoidi
WO2003011897A1 (en) 2001-07-27 2003-02-13 The Regents Of The University Of California Modulation of heregulin and her3 interaction
EP1283053A1 (en) 2001-08-09 2003-02-12 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Inhibitors of HER3 activity
PL213948B1 (pl) 2001-10-25 2013-05-31 Genentech Inc Kompozycje zawierajace glikoproteine, czasteczka kwasu nukleinowego kodujaca te glikoproteine, komórka gospodarza, sposób wytwarzania glikoproteiny, kompozycja do zastosowania do leczenia, zastosowanie kompozycji i zestaw zawierajacy kompozycje
US7771951B2 (en) 2001-12-03 2010-08-10 Amgen Fremont Inc. Antibody categorization based on binding characteristics
EP1478648B1 (en) 2002-02-01 2014-04-30 ARIAD Pharmaceuticals, Inc. Phosphorus-containing compounds and uses thereof
US20030157579A1 (en) 2002-02-14 2003-08-21 Kalobios, Inc. Molecular sensors activated by disinhibition
US7335478B2 (en) 2002-04-18 2008-02-26 Kalobios Pharmaceuticals, Inc. Reactivation-based molecular interaction sensors
AU2003217912A1 (en) 2002-03-01 2003-09-16 Xencor Antibody optimization
CN1678634A (zh) 2002-06-28 2005-10-05 多曼蒂斯有限公司 免疫球蛋白单个变体抗原结合区及其特异性构建体
NZ540194A (en) 2002-11-08 2008-07-31 Ablynx Nv Single domain antibodies directed against tumour necrosis factor-alpha and uses therefor
CA2511910A1 (en) 2002-12-27 2004-07-15 Domantis Limited Dual specific single domain antibodies specific for a ligand and for the receptor of the ligand
WO2004072266A2 (en) 2003-02-13 2004-08-26 Kalobios Inc. Antibody affinity engineering by serial epitope-guided complementarity replacement
JP4889493B2 (ja) 2003-05-14 2012-03-07 ドマンティス リミテッド ポリペプチドレパートリーから可逆的にアンフォールドするポリペプチドを回収するための方法
DE10324447A1 (de) 2003-05-28 2004-12-30 Scil Proteins Gmbh Generierung künstlicher Bindungsproteine auf der Grundlage von Ubiquitin
JP5087274B2 (ja) 2003-06-30 2012-12-05 ドマンティス リミテッド ポリペプチド
US7399865B2 (en) 2003-09-15 2008-07-15 Wyeth Protein tyrosine kinase enzyme inhibitors
US7981843B2 (en) 2004-01-20 2011-07-19 Kalobios Pharmaceuticals, Inc. Antibody specificity transfer using minimal essential binding determinants
US20060008844A1 (en) 2004-06-17 2006-01-12 Avidia Research Institute c-Met kinase binding proteins
JP2008528010A (ja) 2005-01-31 2008-07-31 アブリンクス ナームローゼ フェンノートシャップ 重鎖抗体の可変ドメイン配列を作出する方法
GB0503546D0 (en) * 2005-02-21 2005-03-30 Hellenic Pasteur Inst Antibody
GB0510390D0 (en) 2005-05-20 2005-06-29 Novartis Ag Organic compounds
KR20080080482A (ko) 2005-09-07 2008-09-04 메디뮨 엘엘씨 독소가 컨쥬게이트된 ｅｐｈ 수용체 항체
CA2618489A1 (en) 2005-09-07 2007-03-15 Laboratoires Serono S.A. Pi3k inhibitors for the treatment of endometriosis
KR101866623B1 (ko) 2005-11-28 2018-07-04 젠맵 에이/에스 재조합 １가 항체 및 그의 제조 방법
AR056857A1 (es) 2005-12-30 2007-10-24 U3 Pharma Ag Anticuerpos dirigidos hacia her-3 (receptor del factor de crecimiento epidérmico humano-3) y sus usos
AU2007257683A1 (en) 2006-06-12 2007-12-21 Symphogen A/S Pan-cell surface receptor- specific therapeutics
KR20090058512A (ko) * 2006-08-04 2009-06-09 아스트라제네카 아베 Ｅｒｂｂ2에 대한 인간 항체
AU2007287794B2 (en) * 2006-08-21 2013-03-28 F. Hoffmann-La Roche Ag Tumor therapy with an anti-VEGF antibody
US7825127B2 (en) 2006-12-28 2010-11-02 Takeda Pharmaceutical Company, Limited Method for treating cancer
NZ579644A (en) 2007-02-16 2012-05-25 Merrimack Pharmaceuticals Inc Antibodies against erbb3 and uses thereof
MX2009008981A (es) 2007-03-02 2009-09-02 Genentech Inc Prediccion de respuesta a un inhibidor her.
US20080245375A1 (en) 2007-04-05 2008-10-09 Medtronic Vascular, Inc. Benign Prostatic Hyperplasia Treatments
BRPI0816769A2 (pt) 2007-09-12 2016-11-29 Hoffmann La Roche combinações de compostos inibidores de fosfoinositida 3-cinase e agentes quimioterapêuticos, e métodos de uso
RU2010119556A (ru) 2007-10-16 2011-11-27 Симфоген А/С (Dk) Композиции, содержащие оптимизированные мультимеры her1 и her3, и способы их применения
WO2009055730A1 (en) 2007-10-25 2009-04-30 Genentech, Inc. Process for making thienopyrimidine compounds
UY31800A (es) 2008-05-05 2009-11-10 Smithkline Beckman Corp Metodo de tratamiento de cancer usando un inhibidor de cmet y axl y un inhibidor de erbb
JP2012525432A (ja) 2009-04-29 2012-10-22 トレリス バイオサイエンス リミテッド ライアビリティー カンパニー ヘレグリン共役型ｈｅｒ３と免疫反応性の改善された抗体
AU2010284018C1 (en) 2009-08-21 2015-10-15 Merrimack Pharmaceuticals, Inc. Antibodies against the ectodomain of ErbB3 and uses thereof
US8654108B2 (en) 2009-09-25 2014-02-18 Sharp Kabushiki Kaisha Liquid crystal display device
JP2013507926A (ja) 2009-10-14 2013-03-07 メリマック ファーマシューティカルズ インコーポレーティッド ＩＧＦ−１Ｒ及びＥｒｂＢ３シグナル伝達を標的とする二重特異的結合剤及びその使用
KR101806323B1 (ko) 2009-11-13 2017-12-07 다이이치 산쿄 유럽 게엠베하 Ｈｅｒ-３ 관련 질병을 치료하거나 예방하기 위한 물질 및 방법
PH12012501157A1 (en) 2009-12-22 2012-10-29 Roche Glycart Ag Anti-her3 antibodies and uses thereof
ES2519348T3 (es) 2010-02-18 2014-11-06 Genentech, Inc. Antagonistas de neurregulina y uso de los mismos en el tratamiento del cáncer
US8895001B2 (en) 2010-03-11 2014-11-25 Merrimack Pharmaceuticals, Inc. Use of ErbB3 inhibitors in the treatment of triple negative and basal-like breast cancers
KR101764453B1 (ko) 2010-04-09 2017-08-02 아베오 파마슈티컬즈, 인크. 항-erbb3 항체
CA2799217A1 (en) 2010-05-13 2011-11-17 Fox Chase Cancer Center Recombinantly produced antibodies targeting erbb signaling molecules and methods of use thereof for the diagnosis and treatment of disease
US9932403B2 (en) 2010-05-20 2018-04-03 Ablynx Nv Biological materials related to HER3
UY33492A (es) 2010-07-09 2012-01-31 Abbott Lab Inmunoglobulinas con dominio variable dual y usos de las mismas
WO2012019024A2 (en) 2010-08-04 2012-02-09 Immunogen, Inc. Her3-binding molecules and immunoconjugates thereof
AU2011286407A1 (en) 2010-08-06 2013-02-21 Amgen Use of HER3 binding agents in prostate treatment
ME02637B (me) 2010-08-20 2017-06-20 Novartis Ag Antitela za receptor 3 faktora rasta epiderma (her3)
TW201302793A (zh) 2010-09-03 2013-01-16 Glaxo Group Ltd 新穎之抗原結合蛋白
US9155802B2 (en) 2010-11-01 2015-10-13 Symphogen A/S Pan-HER antibody composition
ITRM20100577A1 (it) 2010-11-02 2012-05-03 Takis Srl Immunoterapia contro il recettore erbb-3
UY33707A (es) 2010-11-04 2012-05-31 Abbott Lab Inmunoglobulinas con dominio variable dual y usos de las mismas
NO2707391T3 (me) 2011-05-13 2018-04-07
CA2842860A1 (en) 2011-07-28 2013-01-31 Sea Lane Biotechnologies, Llc Sur-binding proteins
EP2788382A2 (en) 2011-12-05 2014-10-15 Novartis AG Antibodies for epidermal growth factor receptor 3 (her3) directed to domain ii of her3
CN108341873B (zh) * 2011-12-05 2022-03-25 诺华股份有限公司 表皮生长因子受体3(her3)的抗体

Also Published As

Publication number Publication date
BR112013004012B1 (pt) 2021-03-23
CN103080134A (zh) 2013-05-01
LT2606070T (lt) 2017-04-10
NZ607337A (en) 2015-06-26
ES2620255T3 (es) 2017-06-28
JP2019001791A (ja) 2019-01-10
DK2606070T3 (en) 2017-03-27
GT201300046A (es) 2015-06-02
CN105037552A (zh) 2015-11-11
IL261916A (en) 2018-10-31
US20190194347A1 (en) 2019-06-27
MX2013002046A (es) 2013-04-03
JP6057896B2 (ja) 2017-01-11
CR20130071A (es) 2013-03-13
SG187908A1 (en) 2013-03-28
HRP20170462T1 (hr) 2017-05-19
JP2017019815A (ja) 2017-01-26
PH12013500333A1 (en) 2013-04-22
JP2018090590A (ja) 2018-06-14
CO6680688A2 (es) 2013-05-31
EP2606070A1 (en) 2013-06-26
UA114883C2 (uk) 2017-08-28
KR20130108304A (ko) 2013-10-02
GEP201706605B (en) 2017-01-25
WO2012022814A1 (en) 2012-02-23
CY1118761T1 (el) 2017-07-12
JP2013537546A (ja) 2013-10-03
JP6770944B2 (ja) 2020-10-21
SMT201700217T1 (it) 2017-05-08
PT2606070T (pt) 2017-03-31
MY162825A (en) 2017-07-31
CA2806637C (en) 2020-08-25
NI201300023A (es) 2013-04-15
PL2606070T3 (pl) 2017-06-30
DOP2013000044A (es) 2013-05-31
US10077317B2 (en) 2018-09-18
US8735551B2 (en) 2014-05-27
US20120107306A1 (en) 2012-05-03
SI2606070T1 (sl) 2017-04-26
BR112013004012A2 (pt) 2016-06-28
MA34524B1 (fr) 2013-09-02
CU24094B1 (es) 2015-04-29
CU20130023A7 (es) 2013-05-31
JP6416161B2 (ja) 2018-10-31
KR102027011B1 (ko) 2019-09-30
IL226712B (en) 2018-10-31
JP6771002B2 (ja) 2020-10-21
AU2011290672A1 (en) 2013-03-21
CA2806637A1 (en) 2012-02-23
CN105037552B (zh) 2019-03-29
EA036314B1 (ru) 2020-10-26
HUE031855T2 (en) 2017-08-28
CL2013000459A1 (es) 2014-01-31
US20170166653A1 (en) 2017-06-15
EA201300256A1 (ru) 2013-08-30
EP2606070B1 (en) 2016-12-21
RS55930B1 (sr) 2017-09-29
AU2011290672B2 (en) 2015-07-09
PL2606070T4 (pl) 2017-06-30
PE20140230A1 (es) 2014-02-26
CN103080134B (zh) 2015-11-25
CL2014002750A1 (es) 2015-04-06

Similar Documents

Publication Publication Date Title
HRP20170462T1 (hr) Protutijela za epidermalni receptor 3 faktora rasta (her3)
US20220348683A1 (en) Antibody that binds erbb-2 and erbb-3
JP2013537546A5 (me)
Merchant et al. Monovalent antibody design and mechanism of action of onartuzumab, a MET antagonist with anti-tumor activity as a therapeutic agent
US8552157B2 (en) c-Kit antibodies and uses thereof
Ko et al. Combination of novel HER2‐targeting antibody 1E11 with trastuzumab shows synergistic antitumor activity in HER2‐positive gastric cancer
RU2011111746A (ru) Композиции рекомбинантных антител против рецептора эпидермального фактора роста
RU2012151823A (ru) Антитела против рецептора эпидермального фактора роста (egfr) и их применение
AU2013255537A1 (en) Humanized pan-her antibody compositions
WO2019241893A2 (en) Anti-her3 antibody and uses thereof
EP3169708B1 (en) Her3 inhibition in low-grade serous ovarian cancers
JP2020515594A (ja) Ｅｒｂｂ−２、ｅｒｂｂ−２／ｅｒｂｂ−３陽性腫瘍を有する個体の処置のための、ｅｒｂ−２及びｅｒｂｂ−３の細胞外部分上のエピトープに結合する抗原結合部位を含むｅｒｂｂ−２標的化剤及び二重特異性抗体
Rodems et al. Adaptive responses to antibody based therapy
고봉국 Studies of synergistic antibody combination for treatment of patients with HER2-positive cancer
HK40006122A (en) Antibody that binds erbb-2 and erbb-3
HK40006122B (en) Antibody that binds erbb-2 and erbb-3